A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
263actual
Sites
38
Countries
Canada, Poland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-09 | actual | When the study began enrolling |
| Primary completion | 2025-10-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: PF-07976016
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in body weight
measured Baseline to Week 16
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed